Cargando…
The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke
Ischemic stroke (IS) is a common neurological disorder associated with high disability rates and mortality rates. At present, recombinant tissue plasminogen activator (r-tPA) is the only US(FDA)-approved drug for IS. However, due to the narrow therapeutic window and risk of intracerebral hemorrhage,...
Autores principales: | Li, Xing-Hua, Yin, Feng-Ting, Zhou, Xiao-Hang, Zhang, Ai-Hua, Sun, Hui, Yan, Guang-Li, Wang, Xi-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148018/ https://www.ncbi.nlm.nih.gov/pubmed/35630576 http://dx.doi.org/10.3390/molecules27103099 |
Ejemplares similares
-
The identification and molecular mechanism of anti-stroke traditional Chinese medicinal compounds
por: Liu, Jia-Qian, et al.
Publicado: (2017) -
Traditional Chinese medicine for COVID-19 treatment
por: Ren, Jun-ling, et al.
Publicado: (2020) -
Functional annotation map of natural compounds in traditional Chinese medicines library: TCMs with myocardial protection as a case
por: Xing, Xudong, et al.
Publicado: (2023) -
Therapeutic potential of natural compounds from Chinese medicine in acute and subacute phases of ischemic stroke
por: Zhang, Bei, et al.
Publicado: (2019) -
Traditional Chinese medicine in treating ischemic stroke by modulating mitochondria: A comprehensive overview of experimental studies
por: Liu, Lu, et al.
Publicado: (2023)